Ulcerative Colitis

Cosmo gets to the bottom of IBD

Cosmo gets to the bottom of IBD

By Katrina Megget

Cosmo Pharmaceuticals is cementing its place in the inflammatory
bowel disease (IBD) drug market with eight new drugs in various
stages of reformulation using the company's cutting-edge MMX
technology, the company announced recently.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers